Assembly Biosciences Inc
ASMB
查看详细走势图
26.790USD
-2.080-7.20%
交易中 （美东）报价延迟15分钟
5.56M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-7.20%
5天
-5.87%
1月
-10.22%
6月
+8.77%
今年开始到现在
-21.23%
1年
+152.26%
查看详细走势图
TradingKey Assembly Biosciences Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Assembly Biosciences Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名66/391位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价47.75。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Assembly Biosciences Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Assembly Biosciences Inc亮点
亮点风险
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
业绩高增长
公司营业收入稳步增长，连续3年增长909.40%
业绩增长期
公司处于发展阶段，最新年度总收入72.30M美元
估值低估
公司最新PE估值-50.73，处于3年历史低位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值572.90K
分析师目标
根据
4
位分析师
强力买入
评级
47.750
目标均价
+65.40%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Assembly Biosciences Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Assembly Biosciences Inc简介
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
公司代码ASMB
公司Assembly Biosciences Inc
CEO
网址https://www.assemblybio.com/
相关品种
